Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SK Acquires Rights to Radiopharmaceutical in $571 Million Agreement

publication date: Jul 17, 2024

SK Biopharmaceuticals of South Korea in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies in a deal worth up to $571.5 million. SK Bio will develop Full-Life's FL-091 radiopharmaceutical compound to treat neurotensin receptor 1 (NTSR1) positive cancers. FL-091 is a small-molecule radioligand vector that delivers targeted radiation therapy to cancer cells by binding to NTSR1, a receptor protein overexpressed in colorectal, prostate and pancreatic cancers. Last year, SK Bio said it would focus on developing radiopharmaceutical candidates. SK will have all rights to the candidate, including manufacturing and commercialization. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here